當(dāng)前位置：首頁 SCI期刊 SCIE期刊醫(yī)學(xué) 中科院2區(qū) JCRQ1 期刊介紹(非官網(wǎng))

Drug Design Development And TherapySCIE

國際簡稱：DRUG DES DEV THER 參考譯名：藥物設(shè)計開發(fā)和治療

中科院分區(qū)
2區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：1177-8881; 是否OA：開放; 是否預(yù)警：否; TOP期刊：是

出版信息：: 出版地區(qū)：ENGLAND; 出版商：Dove Medical Press Ltd.; 出版語言：English; 出版周期：1 issue/year; 出版年份：2007; 研究方向：CHEMISTRY, MEDICINAL-PHARMACOLOGY & PHARMACY

評價信息：: 影響因子：4.7; H-index：48; CiteScore指數(shù)：9; SJR指數(shù)：0.999; SNIP指數(shù)：1.124

發(fā)文數(shù)據(jù)：: Gold OA文章占比：97.50%; 研究類文章占比：80.08%; 年發(fā)文量：256; 自引率：0; 開源占比：0.9689; 出版撤稿占比：0.0043...; 出版國人文章占比：0.52; OA被引用占比：1

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介Drug Design Development And Therapy期刊介紹

Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.

The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.

Specific topics covered by the journal include:

Drug target identification and validation

Phenotypic screening and target deconvolution

Biochemical analyses of drug targets and their pathways

New methods or relevant applications in molecular/drug design and computer-aided drug discovery*

Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)

Structural or molecular biological studies elucidating molecular recognition processes

Fragment-based drug discovery

Pharmaceutical/red biotechnology

Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**

Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development

Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)

Preclinical development studies

Translational animal models

Mechanisms of action and signalling pathways

Toxicology

Gene therapy, cell therapy and immunotherapy

Personalized medicine and pharmacogenomics

Clinical drug evaluation

Patient safety and sustained use of medicines.

期刊簡介Drug Design Development And Therapy期刊介紹

《Drug Design Development And Therapy》自2007出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個領(lǐng)域的原創(chuàng)研究提供一個展示平臺，以促進醫(yī)學(xué)領(lǐng)域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時報道醫(yī)學(xué)領(lǐng)域的最新進展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點：

預(yù)計審稿時間： 12周，或約稿
國際TOP期刊
醫(yī)學(xué)
CHEMISTRY, MEDICINAL
SCIE
中科院2區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Drug Design Development And Therapy Cite Score數(shù)據(jù)

CiteScore：9
SJR：0.999
SNIP：1.124

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmaceutical Science	Q1	24 / 183	87%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q1	48 / 313	84%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Drug Discovery	Q1	27 / 157	83%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評價。

歷年Cite Score趨勢圖

中科院SCI分區(qū)Drug Design Development And Therapy 中科院分區(qū)

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	2區(qū)	CHEMISTRY, MEDICINAL 藥物化學(xué) PHARMACOLOGY & PHARMACY 藥學(xué)	2區(qū) 2區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運用科學(xué)計量學(xué)方法對國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進行等級劃分的期刊評價標(biāo)準(zhǔn)。它為我國科研、教育機構(gòu)的管理人員、科研工作者提供了一份評價國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個層次，類似于“優(yōu)、良、及格”等。最開始，這個分區(qū)只是為了方便圖書管理及圖書情報領(lǐng)域的研究和期刊評估。之后中科院分區(qū)逐步發(fā)展成為了一種評價學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢圖

JCR分區(qū)Drug Design Development And Therapy JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CHEMISTRY, MEDICINAL	SCIE	Q1	17 / 72	77.1%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	55 / 354	84.6%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：CHEMISTRY, MEDICINAL	SCIE	Q1	17 / 72	77.08%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	68 / 354	80.93%

JCR分區(qū)的優(yōu)勢在于它可以幫助讀者對學(xué)術(shù)文獻質(zhì)量進行評估。不同學(xué)科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計

國家/地區(qū)數(shù)量
CHINA MAINLAND770
USA91
South Korea61
Egypt55
Saudi Arabia53
Italy39
Iran30
GERMANY (FED REP GER)27
Malaysia25
Pakistan25

本刊中國學(xué)者近年發(fā)表論文

1、Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles
Author: Zhu, Yuanyuan; Zhang, Wei; Chen, Jing

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 1-13. DOI: 10.2147/DDDT.S387246
2、Menthone Exerts its Antimicrobial Activity Against Methicillin Resistant Staphylococcus aureus by Affecting Cell Membrane Properties and Lipid Profile
Author: Zhao, Wenming; Yang, Chengwei; Zhang, Ning; Peng, Yuanyuan; Ma, Ying; Gu, Keru; Liu, Xia; Liu, Xiaohui; Liu, Xijian; Liu, Yumin; Li, Songkai; Zhao, Linjing

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 219-236. DOI: 10.2147/DDDT.S384716
3、Evaluation of Chitosan-Oleuropein Nanoparticles on the Durability of Dentin Bonding
Author: Zhao, Shuya; Zhang, Yunyang; Chen, Yun; Xing, Xianghui; Wang, Yu; Wu, Guofeng

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 167-180. DOI: 10.2147/DDDT.S390039
4、Efficacy and Mechanism of Qianshan Huoxue Gao in Acute Coronary Syndrome via Regulation of Intestinal Flora and Metabolites
Author: Zhao, Ning; Ma, Yan; Liang, Xiaoxue; Zhang, Yu; Hong, Dacheng; Wang, Ying; Bai, Dong

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 579-595. DOI: 10.2147/DDDT.S396649
5、Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer
Author: Zhao, Mei; Fu, Lijuan; Xu, Panling; Wang, Ting; Li, Ping

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 901-917. DOI: 10.2147/DDDT.S397969
6、Network Pharmacology and Experimental Validation to Explore That Celastrol Targeting PTEN is the Potential Mechanism of Tripterygium wilfordii (L?v.) Hutch Against IgA Nephropathy
Author: Zhao, Juanyong; Liu, Haiyang; Xia, Ming; Chen, Qian; Wan, Lili; Leng, Bin; Tang, Chengyuan; Chen, Guochun; Liu, Yu; Zhang, Lei; Liu, Hong

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 887-900. DOI: 10.2147/DDDT.S402503
7、Shensong Yangxin Capsule Reduces the Susceptibility of Arrhythmia in db/db Mice via Inhibiting the Inflammatory Response Induced by Endothelium Dysfunction
Author: Zhang, Jiehan; Li, Hongrong; Wang, Dandong; Gu, Jiaojiao; Hou, Yunlong; Wu, Yiling

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 313-330. DOI: 10.2147/DDDT.S392328
8、Review on the Diverse Biological Effects of Glabridin
Author: Zhang, Jianhong; Wu, Xinhui; Zhong, Baiyin; Liao, Qicheng; Wang, Xin; Xie, Yuankang; He, Xiao

Journal: DRUG DESIGN DEVELOPMENT AND THERAPY. 2023; Vol. 17, Issue , pp. 15-37. DOI: 10.2147/DDDT.S385981